Free shipping over €250 · Tracked, discreet delivery in Europe

Cyclic glycine-proline analogue

NNZ-2591

In clinical trialsNot yet reviewedPeptide

In short: A synthetic analogue of a natural IGF-1 metabolite. In clinical trials for rare neurodevelopmental disorders.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is NNZ-2591 an approved medicine?

In clinical trials. In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

How much human research is there on NNZ-2591?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply NNZ-2591?

No. It appears in the library for reference only, so the field can be read in one place.

More in Brain, mood & sleep

Back to the library
  • Researchuu

    Selank

    Tuftsin analogue

    Early human data
  • Researchuu

    Semax

    ACTH(4-10) analogue

    Mixed evidence
  • Researchuu

    DSIP

    Neuropeptide

    Mixed evidence
  • Researchuu

    Pinealon

    Short bioregulator peptide

    Preclinical
  • Researchuu

    Dihexa

    Angiotensin IV analogue

    Preclinical
  • Researchuu

    ARA-290

    Erythropoietin-derived peptide

    Early human data

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.